×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Sessions 12, 13, 14, 15, and 16
Session Chair(s)
Albert S. Yehaskel, MBA
President and CEO
Refuah Global Pharmaceutical Development, Inc., United States
Session 12: Drug Master Files
- Regulatory Basis
- DMF Submissions
- Transmittal Letter
- Administrative Information
- FDA Review of DMFs
- Types I, II, III, IV, and V DMFs
- General Suggestions
- Letters of Authorization
- Holder Obligations
- Transfer of Ownership and Potential Issues
- Organization of Module
- Organization and Review of Module 1
- Organization of Module 2
- The QOS
- Content and Requirements